Rosuvastatin and retinoic acid may act as 'pleiotropic agents' against β-adrenergic agonist-induced acute myocardial injury through modulation of multiple signalling pathways.

Rosuvastatin and retinoic acid may act as 'pleiotropic agents' against β-adrenergic agonist-induced acute myocardial injury through modulation of multiple signalling pathways. Chem Biol Interact. 2020 Jan 30;:108970 Authors: Sultan F, Kaur R, Mir AH, Maqbool I, Lonare M, Singh D, Rampal S, Dar JA Abstract Cardiovascular disorders constitute the principal cause of deaths worldwide and will continue as the major disease-burden by the year 2060. A significant proportion of heart failures occur because of use and misuse of drugs and most of the investigational agents fail to achieve any clinical relevance. Here, we investigated rosuvastatin and retinoic acid for their "pharmacological pleiotropy" against high dose β-adrenergic agonist (isoproterenol)-induced acute myocardial insult. Rats were pretreated with rosuvastatin and/or retinoic acid for seven days and the myocardial injury was induced by administering isoproterenol on the seventh and eighth day. After induction, rats were anaesthetized for electrocardiography, then sacrificed and different samples were collected/stored for various downstream assays. Myocardial injury with isoproterenol resulted in increased cardiac mass, decreased R-wave amplitude, increased QRS and QT durations; elevated levels of cardiac markers like cTnI, CK-MB, ALT and AST; increased lipid peroxidation, protein carbonylation and tissue nitric oxide levels; decreased endogenous antioxidants like SOD, CAT, G...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research